πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK β€” grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≀24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months β€” use filters for patent-cliff planning.

Page 2 of 18

  1. US 12275792

    Antigen-binding proteins that activate the leptin receptor

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12274747

    Compositions and methods for treating cytokine release syndrome

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12269897

    Anti-PCSK9 antibodies

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12269889

    Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12268730

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12264343

    TCRa homing endonuclease variants

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12264366

    Genome-based methods for reducing cardiovascular risk

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12258627

    Kelch domain containing 7B (KLHDC7B) variants and uses thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12258597

    Methods and compositions for therapeutic protein delivery

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12256720

    Humanized dipeptidyl-peptidase IV (DPP4) animals

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12258412

    Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12252544

    Anti-CD63 antibodies, conjugates, and uses thereof

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12250931

    Genetically modified mouse with a humanized PNPLA3 gene and methods of use

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12252530

    Human antibodies to Fel d1 and methods of use thereof

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12252520

    Myosin 15 promoters and uses thereof

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12251440

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12239687

    Sustained release formulations using non-aqueous membrane emulsification

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12240907

    N-terminal scFv multispecific binding molecules

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12240908

    N-terminal scFv multispecific binding molecules

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12234277

    Hydrophobic interaction chromatography for viral clearance

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12234460

    Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12227740

    CBLB endonuclease variants, compositions, and methods of use

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12230364

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12215322

    Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12214023

    Compositions and methods for expressing factor IX

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12215148

    Antigen binding molecule formats

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12215138

    Compositions and methods for internalizing enzymes

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12215131

    IgG Fc-IL2-RΞ±-IL2 fusions and methods of use thereof

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12209180

    Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12209238

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12201673

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12202883

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12186378

    Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12187792

    IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12187772

    IL10 agonists and methods of use thereof

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12180272

    Antigen binding molecule formats

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12168681

    Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12169199

    Activity based host cell protein profiling

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12168036

    Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12161097

    Non-human animals having a humanized signal-regulatory protein gene

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12162943

    High affinity human antibodies to human IL-4 receptor

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12163192

    Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12157891

    Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12157758

    Readily isolated bispecific antibodies with native immunoglobulin format

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12152067

    Human antibodies to ebola virus glycoprotein

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12150959

    Chimeric antigen receptors with BCMA specificity and uses thereof

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12144864

    Tubulysins and protein-tubulysin conjugates

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12139546

    Methods of treating urea cycle disorders by interfering with glucagon receptor signaling

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.